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Patient preference survey in the management of
asymptomatic carotid stenosis
Gayani S. Jayasooriya, BSc, MBBS, Joseph Shalhoub, BSc, MBBS, MRCS,
Ankur Thapar, BSc, MBBS, MRCS, and Alun H. Davies, MA, DM, FRCS, London, United Kingdom
Objectives: Carotid stenosis accounts for 20% of ischemic strokes and can be managed with pharmacotherapy alone or in
conjunction with carotid endarterectomy or stenting. The management of asymptomatic carotid stenosis is controversial
amongst physicians. The aim of this study was to explore patient preferences for the potential management options using
a standardized scenario to minimize clinician bias. These data will then be used to facilitate comparison with existing
published data on physicians’ preferences in the management of asymptomatic carotid stenosis.
Methods: A patient information booklet and questionnaire was developed, validated, and distributed to patients who were
identified as candidates for carotid screening duplex based on the presence of peripheral arterial, coronary, or aneurismal
disease. Patients were asked to imagine their duplex revealed a 70% unilateral carotid stenosis. Five-year stroke or death
risks of 11% were quoted for best medical therapy. The perioperative stroke or death rates quoted were 3% for
endarterectomy and 3% to 5% for stenting, based on best current evidence. No physician interaction was allowed to
minimize clinician bias. Responses for treatment preference and reasoning were analyzed using appropriate statistical
methods. Results from this survey were then compared with a previously published poll of physician preference.
Results:One hundred two questionnaires were analyzed with a 94% response rate: 48% chose pharmacotherapy alone, 30%
selected carotid endarterectomy, and 22% opted for stenting. The preference for pharmacotherapy alone over either
intervention, and for endarterectomy, over stenting was consistent in subgroup analyses by age, gender, prior stroke,
family history of stroke, and smoking status.
Conclusion: In this scenario, patients were split equally between medical and surgical treatment of asymptomatic carotid
stenosis. This was identical to a recent poll of physicians. Tools for risk assessment and the results of the SPACE2,
ACST2, and ACT1 trials would benefit patients and physicians making this important treatment decision. (J Vasc Surg
2011;53:1466-72.)
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lStroke is the third most common cause of death in the
United Kingdom1 and is the leading cause of serious dis-
ability2 and costs the UK National Health Service around
£2.8 billion per year.3 Carotid stenosis is implicated as the
cause in up to 20% of patients.4 The management of
asymptomatic carotid stenosis can involve current best
medical therapy (BMT) with or without carotid endarter-
ectomy (CEA).5,6 Recently, carotid artery stenting (CAS)
has attracted attention as a minimally invasive alternative to
CEA.7
Recent articles have identified a divergence of opinion
amongst physicians in how asymptomatic carotid stenosis
should be managed.8-11 A 2008 poll of 4669 international
healthcare professionals identified a 50:50 split between
intervention and medical therapy.12 The Stenting and An-
gioplasty with Protection in Patients at High Risk for
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1466ndarterectomy (SAPPHIRE) trial failed to demonstrate a
ignificant advantage of CAS over CEA.13 The recently
ompleted Carotid Revascularization Endarterectomy ver-
us Stenting Trial (CREST) also suggests that there is no
ifference in composite outcome between CAS and CEA in
symptomatic carotid stenosis.14 The situation is further
omplicated by a suggestion that intervention may not
enefit up to 94% of asymptomatic patients, due to the
dvances in BMT with the introduction of statins and
ewer antiplatelet agents.15
This highlights the complexity of choosing between
hree management strategies, for a benefit that may lie
any years in the future. The absolute risk reduction for
ndarterectomy is significant but numerically small at
round 1% per year.16,17 If results of the Asymptomatic
arotid Surgery Trial 2 (ACST2),18 the Asymptomatic
arotid Trial (ACT1),19 and the Stent Supported Percuta-
eous Angioplasty of the Carotid Artery versus Endarter-
ctomy 2 (SPACE2) trial19,20 show similar outcomes be-
ween carotid stenting and endarterectomy, two equally
alid interventional options may exist. The last trial incor-
orates a third arm to address the benefit of contemporary
MT alone.
Evidence-based medicine requires integration of best
vailable evidence with clinical experience and patient
hoice,21 particularly in the setting of a complex prophy-
actic intervention. This has previously been evaluated suc-
essfully with aortic aneurysm surgery.22,23 However, no
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Volume 53, Number 6 Jayasooriya et al 1467studies to date have explored patient preference in the
management of asymptomatic carotid stenosis.
The aim of this study was to provide a relevant patient
population24 with a standardized scenario with the current
best evidence from which to make an informed treatment
decision and to explore the reasons behind this. Results of
this survey, in conjunction with evidence from three ongo-
ing trials,18-20 may prove useful inmaking decisions regard-
ing management and resource allocation, particularly in the
setting where different treatment modalities present clinical
equipoise.
METHODS
Development and validation of information
booklet. A patient information booklet explaining the di-
agnosis of carotid stenosis and its natural history was devel-
oped following a literature search of studies, topical reviews,
and patient decision aids.5,7,13,16,18,20,25-31 Quality of the
information booklet was assessed using the International Pa-
tient Decision Aids Standards (IPDAS) guidelines.32 The
readability of three randomly selected paragraphs of 100
words was calculated to give an average reading level of 10
years of school education.33 The booklet was reviewed by staff
within the department of Vascular Surgery at Charing Cross
Hospital, at every level from medical student to consultant,
and was subjected to an external peer review process by a
consultant vascular surgeon and expert patient.
Patients were then asked to imagine their carotid du-
plex examination revealed unilateral 70% asymptomatic
carotid stenosis. This degree of stenosis was chosen to
enable a direct comparison with a large poll of healthcare
professionals.12 The options of BMT, CEA  BMT, and
CAS  BMT were explained at length with suitable illus-
trations. Periprocedural endarterectomy complication rates
were taken from the Cochrane meta-analysis of the ACAS,
ACST, and Veterans Affairs trials.34 Periprocedural stent-
ing complication rates were quoted at a range to reflect
results of the CREST lead-in phase for asymptomatic patients
(3.8%),35 large stenting registries (3.2%),36 and SAPPHIRE
(5.4%).13 The periprocedural stroke or death rates were there-
fore quoted as 3% for CEA and 3% to 5% for CAS. A 5-year
stroke or death risk of 11% was quoted for BMT, 6% for CEA
with BMT, from the ACAS trial,17 and the 5-year ACST
results.16 It was acknowledged that less was known about the
long-term effects of carotid stenting.
Development of the questionnaire. The question-
naire consisted of precoded, free text, and polar (yes/no/don’t
know) questions and addressed the following areas: (1) treat-
ment preference; (2) reasoning behind preference; (3) accept-
able level of periprocedural risk; (4) when to revisit options;
(5) demographics, medical history; and (6) feedback on the
information booklet and questionnaire.
Face and content validity were assessed by 10 one-to-
one patient interviews. Content validity was addressed
through review by an internal and external consultant
expert. Recall validity between patient responses and their
clinical notes was calculated (10 patients; 190 data points).
Observed agreement was 97% and Cohen’s  was 0.94 p95% CI 0.89-0.97). Test–retest validity was calculated for
0 patients (282 data points) who repeated the question-
aire at a mean of eight days (SD  1 day) later. Observed
greement was 91% and Cohen’s  was 0.82 (95% CI
.72-0.92). None of the patients altered their preferred
anagement choice on retesting. The information booklet
nd questionnaire are provided as supplementary material.
Ethical review. Ethical review was undertaken by the
iverside Research Ethics Committee (REC) in February
010 and deemed unnecessary (REC Reference 10/
0706/13).
Inclusion and exclusion criteria. Adult patients who
ere 80 years of age and who were candidates for carotid
maging based on the presence of stable peripheral arterial,
oronary, or aneurysmal disease were recruited from vascular
utpatient clinics and inpatient lists. Subjects were excluded
f they were unable to read or write English, had a diagnosis of
ementia, had previously been screened for carotid disease, or
ad a concurrent malignancy or other life limiting condition.
xclusion criteria for returned surveys were not stating a
reatment preference, answering “don’t know” or not answer-
ng 50% of polar questions.
Survey methodology. The survey was administered in
erson to consecutive consenting participants over a 6-week
eriod in February and March 2010. Patients were allowed as
uch time as they required to read the information booklet
nd complete the questionnaire. No further discussion was
ermitted to avoid the risk of introducing clinician bias. No
ompensation was provided for patient participation.
Data analysis. Statistical analysis of anonymized data
as performed using Prism Version 5·03 (GraphPad Soft-
are Inc, for Windows; San Diego, Calif). Normally, distrib-
ted data were described using means and their standard
rrors (SEM), and parametric statistical tests employed. Non-
ormally distributed data were described using medians and
nterquartile ranges (IQR), and nonparametric statistical
ests used. Categorical data (eg, number of patients selecting
ach treatment option) were compared using Fisher exact test.
wo-tailed tests were used and statistical significance was
aken as P  .05.
ESULTS
One hundred nine consecutive patients fulfilling the
nclusion criteria over a 6-week period were invited to
articipate and of these, 104 completed the questionnaire.
f five that did not take part, one was blind, another was
nable to write, and three opted out. Of returned question-
aires, two were excluded as 50% polar questions were
nanswered. This resulted in 102 questionnaires in the final
nalysis; a 94% response rate.
Demographics. Ninety-three patients were recruited
rom vascular outpatient clinics and nine were inpatients. Of
urvey respondents, 71% were male, mean age was 70 years
SD  11.5 years), with 56 patients (55%) 70 years old.
ighty-five patients (83%) reported that they had peripheral
rterial disease, and the remainder were being screened for
bdominal aortic aneurysms. Sixty-six percent reported hy-
ertension, 64% hypercholesterolemia, 20% diabetes, 19% myo-
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June 20111468 Jayasooriya et alcardial infarction, 8% stroke, and 3% transient ischemic
attack in another arterial territory. Twenty-one percent were
current smokers, 66% were ex-smokers, and 13% reported that
they had never smoked (Table I).
Management preferences. After reading the informa-
tion booklet, 48% selected BMT and 52% opted for a
procedure. Thirty percent chose CEA and 22% preferred
CAS (Fig 1, A and Table II). Fig 1, B demonstrates the
results from the previously conducted online physician
preference poll12 for comparison. The mean age of patients
choosing BMT was 73 years (SD 9.8 years), for CEA 68
Table I. Characteristics of the sample population
Gender Male 72/10
Age 70 years 46/10
Yes
Smoking status 21/102 (21%)
Yes
Diabetes mellitus 20/102 (20%)
Hypertension 67/102 (66%)
Hypercholesterolemia 65/102 (64%)
Stroke 8/102 (8%)
TIA 3/102 (3%)
Myocardial infarction 19/102 (19%)
Peripheral arterial disease 85/102 (83%)
Dialysis 1/102 (1%)
Previous neck surgery 2/102 (2%)
CVA in 1st degree relative 31/102 (30%)
Antihypertensives 70/102 (69%)
Aspirin 71/102 (70%)
Statin 80/102 (78%)
Clopidogrel 12/102 (12%)
Warfarin 12/102 (12%)
Insulin 9/102 (9%)
Oral hypoglycemics 12/102 (12%)
CVA, Cerebrovascular accident; TIA, transient ischemic attack.
A breakdown of the sample population characteristics by gender, age, smok
Fig 1. Preferences in the management of asymptomatic carotid
stenosis. A, Patient preference in this study. B, The results of
an online poll of healthcare professionals conducted by the
New England Journal of Medicine (NEJM).8,12 BMT, Best
medical therapy; CAS, carotid artery stenting; CEA, carotid
endarterectomy.years (SD 12.7 years), and for CAS 65 years (SD 11.8 (ears). Those who chose stenting were significantly
ounger than those choosing BMT (P  .006).
On subgroup analysis by age and gender, BMT was
referred by 43% of men and 60% of women, followed by
EA in 35% of men and 20% of women, and CAS in 22% of
en and 20% of women. Those aged70 years chose BMT
n 39% vs 55% in those70 years, CEA in 35% vs 27%, and
AS in 26% vs 18%. Patients who had a first degree relative
ho had suffered a stroke were equally likely to choose
ntervention than those who did not (52% vs 53%, respec-
ively). A larger proportion of patients who had suffered a
ontralateral event chose BMT compared with those who
ad never had a stroke or transient ischemic attack (TIA)
64% vs 47%). Active smokers expressed a modest prefer-
nce for CEA (8/21: 38%) over BMT (7/21: 33%) and
AS (6/21: 29%), while combined results for ex- and
on-smokers demonstrated the sequence of BMT (42/81:
2%) CEA (23/81: 28%) CAS (16/81: 20%). Results
y subgroup are shown in Table II.
Ninety patients provided a response to the question
egarding the acceptable level of risk for periprocedural
troke and death. The median value quoted for acceptable
eriprocedural stroke and death risk was 3% (IQR; 1%-4%).
n subgroup analysis, the acceptable risks quoted by pa-
ients were: BMT, 1.5% (IQR; 1%-3%); CEA, 3% (IQR;
%-4%); and CAS, 4% (IQR; 3%-5%).
The period after which patients choosing BMT wanted
o rediscuss their options with a doctor varied from never to
months. Most patients chose to return within 1 year
%) Female 30/102 (29%)
%) 70 years 56/102 (55%)
Never Ex-smoker
13/102 (13%) 68/102 (66%)
No Don’t know
79/102 (77%) 3/102 (3%)
34/102 (33%) 1/102 (1%)
34/102 (33%) 3/102 (3%)
90/102 (88%) 4/102 (4%)
93/102 (91%) 6/102 (6%)
81/102 (79%) 2/102 (2%)
17/102 (17%) 0/102 (0%)
98/102 (96%) 3/102 (3%)
100/102 (98%) 0/102 (0%)
68/102 (67%) 3/102 (3%)
30/102 (29%) 2/102 (2%)
30/102 (29%) 1/102 (1%)
22/102 (22%) 0/102 (0%)
87/102 (85%) 3/102 (3%)
88/102 (86%) 2/102 (2%)
91/102 (89%) 2/102 (2%)
88/102 (86%) 2/102 (2%)
atus, significant medical conditions, and current medications.2 (71
2 (4522/49; 45%), or if there was evidence of failure of medical
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Volume 53, Number 6 Jayasooriya et al 1469therapy sonographically (7/49: 14%), or if they had a
stroke (5/49: 10%).
Reasoning. The most common reasons for choosing BMT
were avoidance of surgery (21/49; 43%) and periprocedural
risk (13/49; 27%). The majority of subjects opting for CEA
did so because it offered a better periprocedural stroke and
death profile than CAS (30/31; 97%). Main reasons quoted
by those selecting CAS included being minimally invasive
(8/22; 36%), a previous positive experience with stenting
elsewhere in the arterial tree (5/22; 23%), and less cranial
nerve injury (4/22; 18%) (Fig 2).
DISCUSSION
This is the first study eliciting patient preference in the
management of asymptomatic carotid stenosis using a stan-
dardized scenario, using explicit risks, and a validated infor-
mation pack. The results demonstrated that in general
patients were split equally between BMT and intervention.
Pharmacotherapy alone was the single most popular option
across age groups. CEA was the more popular intervention
compared with CAS. The group most likely to opt for
intervention was male smokers under 70. Interestingly, this
sequence of preferences mirrors that expressed by health-
care professionals in an online poll posing a scenario of a
67-year-old man with an asymptomatic stenosis of 70% to
80% (Fig 1).8,12 Naylor et al15 have calculated that up to
94% of the 122,986 interventions performed for asymp-
tomatic carotid stenosis in the United States in 2005 were
Table II. Management preferences
BMT
Management option 49/102 (48%)
BMT —
P value CEA .006a
CAS .0001a
Mean age ( SD) 73 years (9.8 yea
BMT —
P value CEA .053
CAS .006a
Male 31/72 (43%)
Female 18/30 (60%)
P value .133
70 18/46 (39%)
70 31/56 (55%)
P value .115
Smoker 7/21 (33%)
Non-/ex-smoker 42/81 (52%)
P value .149
Previous stroke/TIA 7/11 (64%)
No previous stroke/TIA 43/91 (47%)
P value .353
CVA in 1st degree relative 15/31 (48%)
No CVA in 1st degree relative 32/68 (47%)
CVA in family unknown 3
P value 1.000
BMT, Best medical therapy; CAS, carotid artery stenting; CEA, carotid end
Patient preference for BMT, CEA, and CAS and subgroup analyses by gen
relative.
aSignificant P value differences are denoted in italics.not required to prevent stroke and that the cost of these was yn extra $21 billion. This survey suggests that without
hysician interaction only approximately half of patients
ould choose an intervention.
Although the scenario set here was hypothetical, it has
een demonstrated that the population targeted is indeed a
elevant one. A recent meta-analysis demonstrates a preva-
ence of 14% for70% asymptomatic carotid artery stenosis
n patients with peripheral arterial disease24 and suggests
hat if a screening program was instigated, targeting this
roup for carotid screening rather than a healthy popula-
ion would be appropriate.
In our survey, those patients preferring BMT placed
mphasis on avoidance of the short-term perioperative risk
ssociated with intervention. With current BMT, ipsilateral
schemic event rates as low as 2.12% have been reported.37
hemajority of those choosing BMTwanted to revisit their
ecision within a year. How failure of medical therapy will
e detected at this point is unclear. Should we rely on
rogression of stenosis,38 plaque area,39 microembolic sig-
als,40 gray-scale median,41 or contrast enhanced ultra-
ound?42,43 This is important because three-quarters of
arotid strokes have no preceding TIA.44 If in the future we
anage these patients exclusively with BMT, there will
e an emerging need to develop modalities for noninvasive
dentification of the high-risk carotid plaque, for example
he detection of silent embolization using transcranial
oppler (TCD),45 functional imaging by contrast en-
anced ultrasound (CEUS),46,47 and plaque texture anal-
CEA CAS
31/102 (30%) 22/102 (22%)
.006a .0001a
— .17
.17 —
68 years (12.7 years) 65 years (11.8 years)
.053 .006a
— .223
.223 —
25/72 (35%) 16/72 (22%)
6/30 (20%) 6/30 (20%)
.163 1.000
16/46 (35%) 12/46 (26%)
15/56 (27%) 10/56 (18%)
.397 .342
8/21 (38%) 6/21 (29%)
23/81 (28%) 16/81 (20%)
.430 .384
3/11 (27%) 1/11 (9%)
29/91 (32%) 19/91 (21%)
1.000 .688
8/31 (26%) 8/31 (26%)
23/68 (34%) 13/68 (19%)
0 0
.490 .442
ctomy; CVA, cerebrovascular accident; TIA, transient ischemic attack.
ge, smoking status, previous stroke/TIA, and previous CVA in 1st degreers)
artere
der, asis.48 Of patients choosing CEA, it was clear that their
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death risk compared with CAS. Indeed, the current
periprocedural stroke and death rate for CEA has been
reported to be as low as 1.4% in the asymptomatic subgroup
of CREST.14 The merits of stenting vs endarterectomy will
be further examined by the ongoing ACST2, SPACE2, and
ACT1 trials.
Those who chose CAS were the youngest group. They
preferred to avoid a scar, often had a previous positive
experience of stenting for occlusive disease in the lower
limb, valued the technological advancement of carotid
stenting, and placed more emphasis on avoiding cranial
nerve palsy. They also were prepared to accept a slightly
higher level of periprocedural risk and an unknown long-
term outcome.
The AmericanHeart Association Primary Prevention of
Stroke Guidelines identify a 1.9 relative risk of stroke with
cigarette smoking, which reduces by 50% after 1 year of
cessation and falls to baseline after 5 years.49 They are
therefore a higher risk population. Sixty-seven percent
chose either CEA or CAS compared with 48% of non-
smokers; however, small numbers limit the generalizability
of this finding. We recommend patients be made aware of
reversibility of this risk factor and are offered pharmaco-
therapy and nicotine replacement at the first consultation.
Results of this survey provide clinicians a glimpse of
what factors patients perceive as important when selecting a
treatment strategy; hence, insight into patient expectations
Fig 2. Graph demonstrating the reasoning behind patie
stenting; CEA, carotid endarterectomy.that are important in determining patient satisfaction. Fur- phermore, patient preference may influence decisions sur-
ounding resource allocation, particularly if different treat-
ent options are proven to offer similar risk/benefit
rofiles.
Limitations. The study population was a multicul-
ural, English-speaking population, consisting mostly of male
laudicants. We acknowledge that the survey does not reflect
he views of rural practice, non-English speakers, or particu-
ar ethnic groups. The survey has the greatest external validity
n a tertiary center with a similar demographic to London,
K. However, recent Reduction of Atherothrombosis for
ontinued Health data suggest that this group is relevant
ecause they have an annual cerebrovascular event rate of
.9% per annum.50 As trial data emerge from SPACE2,
CST-2, and ACT 1, the stroke or death rates quoted will
hange.
A point to consider is that quoted stroke and death
isk in asymptomatic populations managed with medical
herapies may not reflect contemporary practice. With
ore aggressive risk factor management, it is possible
hat the benefit derived from current BMT may be better
han presently acknowledged. This may be seen in the
nalysis of temporal changes in stroke risk in ACST.15
his stresses the value of ongoing trials incorporating a
hird arm exploring the benefit of medical therapy
lone.51,52
We specifically posed a hypothetical scenario to com-
are patients’ opinions with physicians’ opinions in a recent
ference. BMT, Best medical therapy; CAS, carotid arterynt preoll. This cannot be extrapolated to real world decisions,
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neck, or the lack of availability of carotid stenting might
alter decision making. We did this explicitly to exclude the
effect of clinician bias and because routine carotid stenting
for asymptomatics is currently not supported.5,6 Clearly,
individual decision making is more complicated but our
survey places patients in equipoise as to the treatment
options. We did not discuss myocardial infarction in the
information booklet. It has subsequently been demon-
strated that the incidence of myocardial infarction in
asymptomatic patients is not significantly different between
CAS and CEA groups in CREST (HR 0.22-1.38,
P  .2).14
CONCLUSION
In this scenario, we have demonstrated that patients
and clinicians have similar overall preferences23 in the man-
agement of asymptomatic carotid stenosis. The most likely
to choose intervention were young, male smokers. Endar-
terectomy was the favored procedure overall; however,
those who preferred stenting were younger. Taken with
current SVS recommendations, patient preference provides
no rationale for an increase in stenting asymptomatic pa-
tients.6 Those who chose best medical therapy valued a
means of monitoring to ensure they are responding. This is
relevant because around 2% of patients still have a stroke or
TIA annually on best medical therapy. Identifying this
group prior to stroke should take a high priority. Results of
trials comparing contemporary BMT, CEA, and CAS in
asymptomatic patients are awaited to provide further data
regarding the risks and benefits of each management strat-
egy.
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